NasdaqGS - Delayed Quote • USD
Jazz Pharmaceuticals plc (JAZZ)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:10 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 15 | 16 |
| Avg. Estimate | 4.18 | 4.7 | 18.93 | 21 |
| Low Estimate | 3.73 | 4.32 | 18.45 | 17.26 |
| High Estimate | 4.83 | 5.04 | 19.75 | 25.65 |
| Year Ago EPS | 3.95 | 4.51 | 18.29 | 18.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 19 | 19 |
| Avg. Estimate | 953.9M | 1.02B | 4.1B | 4.39B |
| Low Estimate | 903.7M | 988M | 4B | 4.13B |
| High Estimate | 1.02B | 1.05B | 4.27B | 4.64B |
| Year Ago Sales | 892.81M | 957.32M | 3.83B | 4.1B |
| Sales Growth (year/est) | 6.80% | 6.60% | 7.00% | 7.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 4.24 | 4.43 | 4.93 | 5.18 |
| EPS Actual | 3.95 | 4.51 | 4.84 | 5.02 |
| Difference | -0.29 | 0.08 | -0.09 | -0.16 |
| Surprise % | -6.80% | 1.80% | -1.80% | -3.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 4.18 | 4.7 | 18.93 | 21 |
| 7 Days Ago | 4.2 | 4.72 | 18.96 | 21.04 |
| 30 Days Ago | 4.2 | 4.72 | 18.95 | 21.06 |
| 60 Days Ago | 4.38 | 4.84 | 19.94 | 21.97 |
| 90 Days Ago | 4.37 | 4.84 | 19.63 | 21.62 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 2 |
| Up Last 30 Days | 2 | 2 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | 2 | 1 |
Growth Estimates
| CURRENCY IN USD | JAZZ | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 5.80% | -- | -- | 6.50% |
| Next Qtr. | 4.20% | -- | -- | 12.00% |
| Current Year | 3.50% | -- | -- | 5.30% |
| Next Year | 10.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 3.90% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 10.23% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/22/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/22/2024 |
| Reiterates | Truist Securities: Buy to Buy | 3/20/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 3/20/2024 |
| Reiterates | Needham: Buy to Buy | 3/20/2024 |
Related Tickers
INCY Incyte Corporation
51.68
+0.98%
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%
BGNE BeiGene, Ltd.
153.58
+3.38%
LEGN Legend Biotech Corporation
45.30
+1.98%
RARE Ultragenyx Pharmaceutical Inc.
44.24
+0.89%
UTHR United Therapeutics Corporation
233.85
-0.89%
EXEL Exelixis, Inc.
23.70
+0.72%
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
AXSM Axsome Therapeutics, Inc.
71.71
+0.27%
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%